Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05700461 · ClinicalTrials.gov registry record · Phase 1
Drug Screening Using Novel IMD in Renal Cell Carcinoma
A Phase 1 study, sponsored by Oliver Jonas.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05700461 is a Phase 1 study that is actively recruiting participants, run by Oliver Jonas. The registered enrollment target is 20 participants.
The verdict
NCT05700461, a Phase 1 study, is actively recruiting participants, sponsored by Oliver Jonas.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC). The name of the intervention(s) involved in this study are: * Implantable Microdevice (IMD) * Surgery (excision of tumor) * Drugs used in this study will only include drugs already used as standard of care for the treatment of metastatic renal cell carcinoma (RCC)
Interventions
- COMBINATION_PRODUCT Implantable Microdevice (IMD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-01 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05700461
The ClinicalTrials.gov registry entry for NCT05700461 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oliver Jonas, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Implantable Microdevice (IMD) is the first listed.
NCT05700461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05700461 about?
NCT05700461 is a clinical study titled "Drug Screening Using Novel IMD in Renal Cell Carcinoma". This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC). The n...
What is the current status of trial NCT05700461?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-12-01. Estimated completion is 2029-08-31.
What interventions are being tested in trial NCT05700461?
The interventions under investigation include: Implantable Microdevice (IMD) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05700461?
This trial is sponsored by Oliver Jonas, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.